|
【结 构 式】 
|
【分子编号】19067 【品名】N-alpha-(tert-Butoxycarbonyl)-N-omega-tosyl-D-arginyl-(N-omega-tosyl)-L-arginyl-L-prolyl-(4(R)-benzyloxy)-L-prolyl-glycyl-L-phenylalanyl-(3-O-benzyl)-L-seryl-(4(R)-benzyloxy)-D-prolyl-(2S,3aS,7aS)-perhydroindol-2-ylcarbonyl-(N-omega-tosyl)-L-arginine methyl ester 【CA登记号】 |
【 分 子 式 】C100H135N19O22S3 【 分 子 量 】2051.48476 【元素组成】C 58.55% H 6.63% N 12.97% O 17.16% S 4.69% |
合成路线1
该中间体在本合成路线中的序号：(XXIII)Compound (XVIII) was submitted to a coupling cycle (deprotection with TFA, and coupling with DIPCDI) to introduce the following amino acid (XXII) yielding the resin (XXIII). The final peptide was liberated from the resin (XXIII) and simultaneously deprotected by treatment with anhydrous HF containing a 10% anisole, and was purified by HPLC over a C18 reverse phase column, using as eluent acetonitrile-water containing a 0.1% of TFA.
| 【1】 Kyle, D.J.; Hiner, R.N. (Scios Inc.); Bradykinin antagonist peptides. JP 1995504155; US 5385889 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XXI) | 19065 | methyl (2S)-2-([[(2S,3aS,7aS)-1-([(2R,4S)-1-[(2S)-2-[((2S)-2-[[2-([[(2S,4R)-1-[((2S)-1-[(2S)-2-amino-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoyl]pyrrolidinyl)carbonyl]-4-(benzyloxy)pyrrolidinyl]carbonyl]amino)acetyl]amino]-3-phe | C82H109N15O17S2 | 详情 | 详情 | |
| (XXII) | 19064 | (2S)-2-[(tert-butoxycarbonyl)amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C18H28N4O6S | 详情 | 详情 | |
| (XXIII) | 19067 | N-alpha-(tert-Butoxycarbonyl)-N-omega-tosyl-D-arginyl-(N-omega-tosyl)-L-arginyl-L-prolyl-(4(R)-benzyloxy)-L-prolyl-glycyl-L-phenylalanyl-(3-O-benzyl)-L-seryl-(4(R)-benzyloxy)-D-prolyl-(2S,3aS,7aS)-perhydroindol-2-ylcarbonyl-(N-omega-tosyl)-L-arginine methyl ester | C100H135N19O22S3 | 详情 | 详情 |